Cantor Fitzgerald Reaffirms Overweight Rating for Zura Bio (NASDAQ:ZURA)

Zura Bio (NASDAQ:ZURA)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a research note issued on Wednesday,Benzinga reports.

Other analysts also recently issued research reports about the stock. HC Wainwright reissued a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a report on Monday, November 18th. Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. Leerink Partners began coverage on shares of Zura Bio in a report on Monday, November 4th. They issued an “outperform” rating and a $15.00 price target on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $26.00 price target on shares of Zura Bio in a report on Thursday, September 19th. Finally, Chardan Capital reduced their price target on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Zura Bio has an average rating of “Buy” and a consensus target price of $15.80.

Zura Bio Stock Down 12.4 %

NASDAQ:ZURA opened at $2.20 on Wednesday. The company has a 50 day moving average price of $3.80 and a 200 day moving average price of $3.82. Zura Bio has a fifty-two week low of $2.00 and a fifty-two week high of $6.35.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.12). On average, sell-side analysts anticipate that Zura Bio will post -0.65 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Parvinder Thiara sold 1,001,633 shares of Zura Bio stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $2.73, for a total value of $2,734,458.09. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 22.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zura Bio

Institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC bought a new position in shares of Zura Bio in the second quarter valued at about $43,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Zura Bio in the third quarter valued at about $46,000. Renaissance Technologies LLC raised its holdings in shares of Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after buying an additional 5,900 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Zura Bio in the third quarter valued at about $62,000. Finally, Valence8 US LP bought a new position in shares of Zura Bio in the third quarter valued at about $71,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.